February 25, 2021
A new partnership between public and private sector institutions aims to advance the adoption of personalised healthcare in Singapore; part of this includes precision oncology for personalised cancer care.
Listen to Associate Professor David Tan, Senior Consultant from the National University Cancer Institute, Singapore speaking with Health Matters with Daniel Martin on CNA938. on what it takes to set up personalized healthcare and how a clinico-genomic database (CGDB) is going to impact cancer care in the future.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system
Delfi Diagnostics’ liquid biopsy test uses machine learning to spot changes in patients’ DNA fragmentation profiles that indicate the presence of cancerous cells.
Singapore Translational Cancer Consortium, National Cancer Centre Singapore, National University Hospital and Roche signed a Memorandum of Understanding (MOU) to leverage data insights and deepen understanding of unique drivers of disease to help improve health outcomes